BCRX Annual Revenue
$331.41 M
+$60.59 M+22.37%
31 December 2023
Summary:
As of January 22, 2025, BCRX annual revenue is $331.41 million, with the most recent change of +$60.59 million (+22.37%) on December 31, 2023. During the last 3 years, it has risen by +$313.60 million (+1760.61%). BCRX annual revenue is now at all-time high.BCRX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Quarterly Revenue
$117.08 M
+$7.75 M+7.09%
30 September 2024
Summary:
As of January 22, 2025, BCRX quarterly revenue is $117.08 million, with the most recent change of +$7.75 million (+7.09%) on September 30, 2024. Over the past year, it has increased by +$23.68 million (+25.36%). BCRX quarterly revenue is now at all-time high.BCRX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX TTM Revenue
$412.58 M
+$30.34 M+7.94%
30 September 2024
Summary:
As of January 22, 2025, BCRX TTM revenue is $412.58 million, with the most recent change of +$30.34 million (+7.94%) on September 30, 2024. Over the past year, it has increased by +$81.17 million (+24.49%). BCRX TTM revenue is now at all-time high.BCRX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Revenue Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +22.4% | +25.4% | +24.5% |
3 y3 years | +1760.6% | +185.6% | +261.8% |
5 y5 years | +1504.7% | +6496.3% | +744.8% |
BCRX Revenue High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +110.9% | at high | +148.3% | at high | +162.5% |
5 y | 5-year | at high | +1760.6% | at high | +3978.2% | at high | +2216.3% |
alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
BioCryst Pharmaceuticals Revenue History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | $117.08 M(+7.1%) | $412.58 M(+7.9%) |
June 2024 | - | $109.33 M(+17.9%) | $382.24 M(+7.6%) |
Mar 2024 | - | $92.76 M(-0.7%) | $355.39 M(+7.2%) |
Dec 2023 | $331.41 M(+22.4%) | $93.40 M(+7.7%) | $331.41 M(+4.4%) |
Sept 2023 | - | $86.74 M(+5.2%) | $317.56 M(+3.6%) |
June 2023 | - | $82.49 M(+19.9%) | $306.64 M(+5.9%) |
Mar 2023 | - | $68.78 M(-13.5%) | $289.68 M(+7.0%) |
Dec 2022 | $270.83 M(+72.3%) | $79.55 M(+4.9%) | $270.83 M(+13.6%) |
Sept 2022 | - | $75.83 M(+15.7%) | $238.44 M(+17.1%) |
June 2022 | - | $65.53 M(+31.3%) | $203.61 M(+8.3%) |
Mar 2022 | - | $49.92 M(+5.9%) | $188.03 M(+19.6%) |
Dec 2021 | $157.17 M(+782.4%) | $47.16 M(+15.0%) | $157.17 M(+37.8%) |
Sept 2021 | - | $40.99 M(-17.9%) | $114.03 M(+44.1%) |
June 2021 | - | $49.96 M(+162.1%) | $79.14 M(+146.9%) |
Mar 2021 | - | $19.06 M(+374.6%) | $32.05 M(+79.9%) |
Dec 2020 | $17.81 M(-63.5%) | $4.02 M(-34.2%) | $17.81 M(-66.7%) |
Sept 2020 | - | $6.10 M(+112.5%) | $53.52 M(+8.8%) |
June 2020 | - | $2.87 M(-40.5%) | $49.19 M(+3.0%) |
Mar 2020 | - | $4.82 M(-87.9%) | $47.77 M(-2.2%) |
Dec 2019 | $48.84 M(+136.5%) | $39.73 M(+2138.0%) | $48.84 M(+312.5%) |
Sept 2019 | - | $1.77 M(+22.6%) | $11.84 M(+2.8%) |
June 2019 | - | $1.45 M(-75.4%) | $11.52 M(-49.0%) |
Mar 2019 | - | $5.89 M(+115.7%) | $22.56 M(+9.3%) |
Dec 2018 | $20.65 M(-18.0%) | $2.73 M(+87.7%) | $20.65 M(-5.3%) |
Sept 2018 | - | $1.45 M(-88.4%) | $21.81 M(-25.1%) |
June 2018 | - | $12.49 M(+214.2%) | $29.12 M(+47.6%) |
Mar 2018 | - | $3.98 M(+2.2%) | $19.73 M(-21.7%) |
Dec 2017 | $25.19 M(-4.4%) | $3.89 M(-55.6%) | $25.19 M(-16.8%) |
Sept 2017 | - | $8.76 M(+182.7%) | $30.28 M(+3.4%) |
June 2017 | - | $3.10 M(-67.2%) | $29.28 M(-5.5%) |
Mar 2017 | - | $9.44 M(+5.1%) | $30.97 M(+17.5%) |
Dec 2016 | $26.35 M(-45.4%) | $8.98 M(+15.7%) | $26.35 M(+19.9%) |
Sept 2016 | - | $7.76 M(+62.2%) | $21.97 M(-12.8%) |
June 2016 | - | $4.79 M(-0.7%) | $25.20 M(-45.5%) |
Mar 2016 | - | $4.82 M(+4.7%) | $46.25 M(-4.2%) |
Dec 2015 | $48.26 M(+254.6%) | $4.60 M(-58.1%) | $48.26 M(-1.7%) |
Sept 2015 | - | $10.99 M(-57.5%) | $49.10 M(+18.7%) |
June 2015 | - | $25.84 M(+278.6%) | $41.35 M(+143.6%) |
Mar 2015 | - | $6.83 M(+25.3%) | $16.98 M(+24.8%) |
Dec 2014 | $13.61 M(-21.5%) | $5.45 M(+68.2%) | $13.61 M(-27.3%) |
Sept 2014 | - | $3.24 M(+120.9%) | $18.73 M(+4.7%) |
June 2014 | - | $1.47 M(-57.6%) | $17.88 M(+3.7%) |
Mar 2014 | - | $3.46 M(-67.3%) | $17.23 M(-0.6%) |
Dec 2013 | $17.33 M(-34.1%) | $10.57 M(+342.3%) | $17.33 M(+59.5%) |
Sept 2013 | - | $2.39 M(+191.0%) | $10.87 M(-23.7%) |
June 2013 | - | $821.00 K(-76.9%) | $14.24 M(-19.2%) |
Mar 2013 | - | $3.55 M(-13.3%) | $17.63 M(-33.0%) |
Dec 2012 | $26.29 M(+33.9%) | $4.10 M(-28.8%) | $26.29 M(-4.1%) |
Sept 2012 | - | $5.76 M(+36.8%) | $27.42 M(+1.9%) |
June 2012 | - | $4.21 M(-65.6%) | $26.90 M(+1.8%) |
Mar 2012 | - | $12.22 M(+133.9%) | $26.43 M(+34.5%) |
Dec 2011 | $19.64 M(-68.5%) | $5.22 M(-0.5%) | $19.64 M(-36.9%) |
Sept 2011 | - | $5.25 M(+40.5%) | $31.11 M(-17.8%) |
June 2011 | - | $3.73 M(-31.3%) | $37.86 M(-9.3%) |
Mar 2011 | - | $5.43 M(-67.4%) | $41.74 M(-33.1%) |
Dec 2010 | $62.38 M(-16.4%) | $16.69 M(+39.1%) | $62.38 M(-38.0%) |
Sept 2010 | - | $12.00 M(+57.6%) | $100.58 M(+1.5%) |
June 2010 | - | $7.62 M(-70.8%) | $99.13 M(+2.9%) |
Mar 2010 | - | $26.07 M(-52.5%) | $96.30 M(+29.1%) |
Dec 2009 | $74.59 M | $54.90 M(+420.4%) | $74.59 M(+38.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2009 | - | $10.55 M(+120.3%) | $53.93 M(+3.2%) |
June 2009 | - | $4.79 M(+9.8%) | $52.28 M(+4.2%) |
Mar 2009 | - | $4.36 M(-87.3%) | $50.15 M(-11.3%) |
Dec 2008 | $56.56 M(-20.6%) | $34.24 M(+285.0%) | $56.56 M(+12.0%) |
Sept 2008 | - | $8.89 M(+234.5%) | $50.49 M(-18.6%) |
June 2008 | - | $2.66 M(-75.3%) | $62.06 M(-14.8%) |
Mar 2008 | - | $10.77 M(-61.8%) | $72.85 M(+2.3%) |
Dec 2007 | $71.24 M(+1046.8%) | $28.17 M(+37.7%) | $71.24 M(+57.8%) |
Sept 2007 | - | $20.46 M(+52.2%) | $45.16 M(+70.5%) |
June 2007 | - | $13.44 M(+46.8%) | $26.48 M(+81.4%) |
Mar 2007 | - | $9.16 M(+337.8%) | $14.60 M(+135.1%) |
Dec 2006 | $6.21 M(+3989.5%) | $2.09 M(+16.9%) | $6.21 M(+50.0%) |
Sept 2006 | - | $1.79 M(+14.9%) | $4.14 M(+73.8%) |
June 2006 | - | $1.56 M(+102.1%) | $2.38 M(+170.1%) |
Mar 2006 | - | $771.00 K(+3589.0%) | $881.90 K(+480.6%) |
Dec 2005 | $151.90 K(-54.9%) | $20.90 K(-34.7%) | $151.90 K(-50.8%) |
Sept 2005 | - | $32.00 K(-44.8%) | $308.90 K(-21.4%) |
June 2005 | - | $58.00 K(+41.5%) | $392.90 K(+4.0%) |
Mar 2005 | - | $41.00 K(-77.0%) | $377.90 K(+12.2%) |
Dec 2004 | $336.90 K(-48.4%) | $177.90 K(+53.4%) | $336.90 K(+1966.9%) |
Sept 2004 | - | $116.00 K(+169.8%) | $16.30 K(-86.7%) |
June 2004 | - | $43.00 K(-130.1%) | $122.30 K(-81.3%) |
Dec 2003 | $653.30 K(-94.1%) | -$142.70 K(-164.3%) | $653.30 K(-17.9%) |
Sept 2003 | - | $222.00 K(-16.5%) | $796.00 K(-19.3%) |
June 2003 | - | $266.00 K(-13.6%) | $986.00 K(+36.9%) |
Mar 2003 | - | $308.00 K(-25.2%) | $720.00 K(-83.5%) |
Sept 2002 | - | $412.00 K(-23.6%) | $4.37 M(-60.2%) |
Mar 2002 | - | $539.00 K(-84.2%) | $10.99 M(-1.5%) |
Dec 2001 | $11.16 M(+236.5%) | $3.42 M(+0.6%) | $11.16 M(+30.6%) |
Sept 2001 | - | $3.40 M(-6.4%) | $8.54 M(+44.7%) |
June 2001 | - | $3.63 M(+416.9%) | $5.90 M(+70.9%) |
Mar 2001 | - | $703.00 K(-12.5%) | $3.45 M(+4.2%) |
Dec 2000 | $3.32 M(+32.6%) | $803.60 K(+5.3%) | $3.32 M(+32.0%) |
Sept 2000 | - | $763.00 K(-35.6%) | $2.51 M(+43.5%) |
June 2000 | - | $1.19 M(+110.1%) | $1.75 M(-36.5%) |
Mar 2000 | - | $564.00 K(>+9900.0%) | $2.76 M(-10.9%) |
Dec 1999 | $2.50 M(-60.9%) | - | - |
Sept 1999 | - | $1000.00(-100.0%) | $3.09 M(-66.0%) |
June 1999 | - | $2.19 M(+338.4%) | $9.09 M(+29.9%) |
Mar 1999 | - | $500.00 K(+25.0%) | $7.00 M(+6.1%) |
Dec 1998 | $6.40 M(+540.0%) | $400.00 K(-93.3%) | $6.60 M(+6.5%) |
Sept 1998 | - | $6.00 M(+5900.0%) | $6.20 M(+1966.7%) |
June 1998 | - | $100.00 K(0.0%) | $300.00 K(-75.0%) |
Mar 1998 | - | $100.00 K(0.0%) | $1.20 M(+100.0%) |
Dec 1997 | $1.00 M(-37.5%) | - | - |
Sept 1997 | - | $100.00 K(-90.0%) | $600.00 K(-25.0%) |
June 1997 | - | $1.00 M(+900.0%) | $800.00 K(-46.7%) |
Mar 1997 | - | $100.00 K(-116.7%) | $1.50 M(0.0%) |
Dec 1996 | $1.60 M(+700.0%) | -$600.00 K(-300.0%) | $1.50 M(-31.8%) |
Sept 1996 | - | $300.00 K(-82.4%) | $2.20 M(+10.0%) |
June 1996 | - | $1.70 M(+1600.0%) | $2.00 M(+400.0%) |
Mar 1996 | - | $100.00 K(0.0%) | $400.00 K(-20.0%) |
Dec 1995 | $200.00 K(-71.4%) | $100.00 K(0.0%) | $500.00 K(-16.7%) |
Sept 1995 | - | $100.00 K(0.0%) | $600.00 K(-14.3%) |
June 1995 | - | $100.00 K(-50.0%) | $700.00 K(0.0%) |
Mar 1995 | - | $200.00 K(0.0%) | $700.00 K(+16.7%) |
Dec 1994 | $700.00 K | $200.00 K(0.0%) | $600.00 K(+50.0%) |
Sept 1994 | - | $200.00 K(+100.0%) | $400.00 K(+100.0%) |
June 1994 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
Mar 1994 | - | $100.00 K | $100.00 K |
FAQ
- What is BioCryst Pharmaceuticals annual revenue?
- What is the all time high annual revenue for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual revenue year-on-year change?
- What is BioCryst Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly revenue year-on-year change?
- What is BioCryst Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM revenue year-on-year change?
What is BioCryst Pharmaceuticals annual revenue?
The current annual revenue of BCRX is $331.41 M
What is the all time high annual revenue for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual revenue is $331.41 M
What is BioCryst Pharmaceuticals annual revenue year-on-year change?
Over the past year, BCRX annual revenue has changed by +$60.59 M (+22.37%)
What is BioCryst Pharmaceuticals quarterly revenue?
The current quarterly revenue of BCRX is $117.08 M
What is the all time high quarterly revenue for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly revenue is $117.08 M
What is BioCryst Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, BCRX quarterly revenue has changed by +$23.68 M (+25.36%)
What is BioCryst Pharmaceuticals TTM revenue?
The current TTM revenue of BCRX is $412.58 M
What is the all time high TTM revenue for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM revenue is $412.58 M
What is BioCryst Pharmaceuticals TTM revenue year-on-year change?
Over the past year, BCRX TTM revenue has changed by +$81.17 M (+24.49%)